<DOC>
	<DOCNO>NCT02285205</DOCNO>
	<brief_summary>Lobeglitazone highly selective peroxisome proliferator-activated receptor-gamma agonist decrease insulin resistance periphery liver result increased insulin-dependent glucose disposal decrease hepatic glucose output . In vivo , It demonstrate Lobeglitazone improve even glycemic lipid control comparison rosiglitazone pioglitazone . Currently , thiazolidinediones pioglitazone drug consider effective therapeutic agent improve non-alcoholic fatty liver disease ( NALFD ) type 2 diabetes ( T2D ) . The aim multicenter , prospective , open-labeled , single-arm , exploratory phase 4 study evaluate efficacy safety Lobeglitazone daily 24 week intrahepatic fat content assess transient elastography ( fibroscan ) T2D NAFLD . Fifty subject T2D NAFLD take Lobeglitazone ( 0.5mg/tablet , orally , 1 tablet daily ) 24 week . Primary endpoint change baseline control attenuation parameter ( CAP ) measure transient elastography ( fibroscan ) treatment Lobeglitazone . Secondary endpoint change baseline glycemic profile ( HbA1c , Glycated albumin ) , Lipid parameter ( Total Cholesterol , Triglycerides , HDL-C , LDL-C ) , Liver function parameter ( AST , ALT , r-GT ) , adverse event trial .</brief_summary>
	<brief_title>A 24 Week , Multicenter , Prospective , Open-labeled , Single-arm , Exploratory Phase 4 Clinical Trial Evaluate Safety Efficacy Lobeglitazone Decreasing Intrahepatic Fat Contents Type 2 Diabetes With NAFLD</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Type Ⅱ diabetes mellitus 2 . Nonalcoholic fatty liver disease : subject CAP ( Controlled Attenuation Parameter ) ≥ 250dB/m measure transient elastography ( fibroscan ) screen test 3 . Age ≥ 20 year 4 . Patients take oral hypoglycemic agent 12 week HbA1c 7.0 8.5 % screen test take metformin monotherapy least 8 week HbA1c 7 9 % screen test 5 . Agreement write informed consent 1 . Patients whose alcohol consumption &gt; 210g/week male 140g/week female 2. chronic B viral hepatitis , chronic C viral hepatitis , Type I diabetes , secondary diabetes 3. history acute chronic metabolic acidosis include diabetic ketoacidosis 4. patient take oral hypoglycemic agent except metformin insulin within recent 8 week 5. experienced hypersensitivity reaction metformin glitazone drug 6. treated corticosteroid least 14 day within 2 month prior Screening 7. history lactic acidosis 8. genetic predisposition galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption 9. condition malnutrition , starvation , cachexia , severe infection , major trauma , hypopituitarism , adrenal insufficiency 10. diagnosed cancer within 2 year chemo radiotherapy cancer treatment 11. history drug abuse chronic alcoholism 12. history heart failure ( NYHA class III IV ) uncontrolled arrhythmia 13. history acute cardiovascular cerebrovascular disease within 12 week prior Screening ( unstable angina , myocardial infarction , transient ischemic attack , cerebral infarct , cerebral hemorrhage , coronary bypass , percutaneous coronary intervention ) 14 . Renal dysfunction : Serum creatinine great 1.5mg/dl male 1.4mg/dl female . 15 . Anemia le 10.5g/dl reason 16 . Pregnant woman nurse mother 17 . Fertile woman practice contraception appropriate method 18. treatment concomitant drug clinical trial within 4 week enrollment 19. agree write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>